Mohamed bin Zayed University of Artificial Intelligence (United Arab Emirates)
Yeda Research and Development Co., Ltd (Israel)
Inventor
Thawakar, Omkar
Rivkind, Alexandre
Ahissar, Ehud
Khan, Fahad
Abstract
A method and system for video instance segmentation includes a recurrent encoder-based network trained by knowledge distillation from a transformer encoder. Real time performance is achieved by replacing the transformer encoder with the trained recurrent encoder for inference. The system includes a video camera to capture a sequence of video frames, a machine learning processing engine for video instance segmentation, and a video output for outputting a sequence of mask instances. The machine learning processing engine is configured with an interchangeable encoder module. During inference, the encoder module is configured with a recurrent encoder having a combination of convolutional and recurrent layers, The recurrent layers capture temporal relationships between the video frames. During training, the encoder module is configured with a teacher transformer encoder for training the recurrent encoder as a student through knowledge distillation. A transformer decoder outputs video instance mask predictions.
G06V 20/40 - ScenesScene-specific elements in video content
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
The present invention provides a cell including a recombinant DNA molecule including a first nucleic acid sequence encoding at least one first polypeptide being an enzyme selected from: inosine monophosphate dehydrogenase (Impdh), guanosine monophosphate synthetase (gmps), nucleotidase 5C (nt5c), polynucleotide phosphorylase (Pnp), or any combination thereof. Further provided is a method of using the cell of the invention, such as for synthesizing guanine.
5266. The ternary Zintl phase is in a crystalline state, and the nanostructure is selected from a nanowire and a film. In the formula X is selected from Eu, Ca, Sr, and Yb; Y is In or Ga; and Z is As or Sb.
C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
H01L 21/00 - Processes or apparatus specially adapted for the manufacture or treatment of semiconductor or solid-state devices, or of parts thereof
4.
HOST TRANSCRIPTOME FECAL BIOMARKERS FOR GASTROINTESTINAL INFLAMMATORY DISORDERS
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Described herein are antimicrobial peptides comprising protein fragments having microbiocidal activity which are degradation products of the proteasome. The antimicrobial peptides are useful in treating bacterial infections, sepsis, and wounds or skin conditions.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Nucleic acid molecule libraries comprising 5' and 3' primer recognition sites and a plurality of molecules comprising a target sequence molecule and a plurality of variant sequence molecules are provided. Kits comprising the nucleic acid molecule libraries are also provided as are methods of determining protein association with a nucleotide sequence and identifying an inhibitor of protein-DNA interaction.
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C40B 50/08 - Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creationParticular methods of cleavage from the liquid support
9.
COMBINATION OF NUCLEIC ACID SEQUENCES ENCODING PROTEINS DERIVED FROM HELICHRYSUM UMBRACULIGERUM, AND ANY TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME
The present invention provides an isolated DNA molecule including at least a first nucleic acid sequence encoding a first protein and at least a second nucleic acid sequence encoding a second protein, wherein the first protein and the second protein are derived from Helichrysum umbraculigerum and belonging to an enzyme family selected from: acyl activating enzyme (AAE), polyketide synthase (PKS), polyketide cyclase (PKC), prenyltransferase (PT), or cannabichromenic acid synthase (CBCAS), and wherein the first protein and the second protein belong to different enzyme families. Further provided are an artificial nucleic acid molecule including the isolated DNA molecule, a transgenic cell, a tissue, or a plant including same. Further provided is a method for synthesizing a cannabinoid, a precursor thereof, or any combination thereof.
This invention provides contact materials comprising doped ceria-based materials and preparation thereof. This invention further comprises stacks and electrostriction actuators comprising the contact materials provided herein.
H10N 30/053 - Manufacture of multilayered piezoelectric or electrostrictive devices, or parts thereof, e.g. by stacking piezoelectric bodies and electrodes by integrally sintering piezoelectric or electrostrictive bodies and electrodes
The present disclosure relates to SUMOylation-targeting chimeras (SUTACs) comprising a SUMOylation enzyme binder group attached to a target protein binder group via a linker and to uses thereof for the treatment of diseases.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Automatic recognition of non-verbal messages in speech, and in particular to detection or analysis of prosodic multilayered analysis of intonation units such as prosodic unit prototypes and their multi-labeled variations, may form a hierarchical classification for the analysis of non¬ verbal information or cues in speech. A speech captured by a microphone is fed to a weakly- supervised deep learning acoustic model for speech recognition and transcription, that may be based on encoder-decoder Transformer architecture, such as Whisper by OpenAI. The model is trained to output multiple words form the text in the captured speech, to identify Intonation Units (IUs) that include one or more words, and associate non-verbal labels to each of the IUs. The labels may indicate a prototype, a discourse function (such as a conversation action), an emotion, an emphasis, or an attitude, as well as a genre of a part of, or whole of, the entire captured speech.
Hadasit Medical Research Services and Development Ltd. (Israel)
Inventor
Elinav, Eran
Cohen, Yotam
Lev-Sagie, Ahinoam
Goldman-Wohl, Debra
Abstract
A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.
The present invention provides a method for early detection or diagnosis of a neurodegenerative disease, disorder, or condition in a subject at risk of developing or suspected of having the neurodegenerative disease, disorder, or condition, the method comprising measuring in a blood sample obtained from the subject or a fraction thereof the levels of at least one biomarker selected from CD38+ peripheral blood mononuclear cells (PBMCs), trigonelline, GLUT1 expression in CD4+ T cells, Th2, Th2/Th1 ratio, naïve T cells, adenosine, allose, and HLA-DR T cells, as well as related methods and kits.
The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the uridine diphosphate (UDP)-glycosyltransferase (UGT) family. Further provided are an artificial nucleic acid molecule including the polynucleotide disclosed herein, a transgenic cell, tissue, or plant including same.
C12P 19/46 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical bound to a cyclohexyl radical, e.g. kasugamycin
16.
PROBES, APPARATUSES AND METHODS FOR USE IN SCANNING PROBE MICROSCOPY
A system is presented for use in Scanning Probe Microscope (SPM) including: a stage for carrying a sample; a head for mounting thereon an AFM cantilever or an STM probe, and a rotation motor associated with the stage or head to perform controllable rotation of one of them with respect to the other to provide desired orientation alignment between them. Also, a probe is provided for conducting measurements on a sample, comprising: a tip having core with apex covered by a layer arrangement having a support layer of vdW material and an active layer, which is 2D material of not more than 10 monolayers coupled by vdW forces and is placed on the support layer to be further away from the core; and an outer exposed layer. The layer arrangement upon contacting a planar surface forms a contact area with a linear dimension of at least 10 nm.
An isolated antibody that binds to a cyclized peptide having an amino acid sequence as set forth in SEQ ID NO: 9 with an EC50 of less than 500 nM, as determined by ELISA is disclosed. Uses of same are also disclosed as well as methods of generating same.
A method of analyzing cell fate over a course of time is disclosed. The method comprises analyzing cells which have been temporally labelled at a predetermined location at at least two different time points using at least two different labels, each of said at least two different labels corresponding to one of said at least two different time points, wherein said cells temporally labelled at said at least two different time points have localized to a target location prior to said analyzing.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
19.
TRANSGENIC HELICHRYSUM UMBRACULIGERUM CELL, TISSUE, OR PLANT
The present invention provides a transgenic Helichrysum umbraculigerum (Less.) cell, tissue, or plant, comprising an artificial DNA molecule. Further provided are a method for producing the transgenic H. umbraculigerum (Less.) cell. tissue, or plant, and a method of using same, such as for synthesizing a cannabinoid, a precursor thereof, or both.
Provided is a topological superconductivity device based on phase control. The invention relies on two key ingredients: at least three superconducting forming at least two SNS junctions with phase winding, and unequal Fermi velocities for the two spin branches transverse to the junction. The two phase differences between the three superconductors define a two-dimensional parameter plane which includes large topological regions. Arrays of topological devices are disclosed which comprise a plurality of individual topological devices. Material platforms are provided which exhibit unequal Fermi velocities.
An apparatus (20) for sampling signals includes a modulo circuit (24), an Analog to Digital Converter (ADC - 28) and processing circuitry (32). The modulo circuit is configured to receive an analog signal (40), and to derive from the analog signal (i) an analog folded signal (48) whose amplitude is limited to a predefined dynamic range, and (ii) side information (36) indicative of instances in which the analog signal transitions between levels corresponding to odd integer multiples of boundaries specifying the dynamic range. The ADC is configured to sample the analog folded signal to produce a digital folded signal (52). The processing circuitry is configured to generate a digital unfolded signal (44), which represents the analog signal both within and outside the dynamic range, based on the digital folded signal and on the side information, and to output the digital unfolded signal.
Provided are compositions-of-matter comprising non-pathogenic bacteria capable of homing to a tumor, said bacteria comprising a heterologous polynucleotide comprising a nucleic acid sequence encoding a Pro Domain (TPD) polypeptide of TNFα Converting Enzyme (TACE), said TPD being devoid of a catalytic domain of said TACE and said TPD being secreted from or presented on a membrane of said bacteria. Also provided pharmaceutical compositions comprising same and methods of using same for treating cancer.
The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) stimulated with an antigen to which the CAR binds specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular, the present invention exemplifies EVs derived from stimulated T-cells expressing CAR that bind specifically to EGFR, CD276 or CD19, a pharmaceutical composition comprising these EVs and their use in treating cancer overexpressing EGFR, CD276 or CD 19, such as ovarian cancer and breast cancer.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The invention provides agonistic and non-agonistic antibodies that specifically bind Glucocorticoid-induced TNFR-related (GITR) protein, comprising a modified human constant region (Fc) and optionally reduced fucosylation content. Also provided are polynucleotide sequences encoding the antibodies, pharmaceutical compositions thereof and methods of treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention concerns methods and systems for vascular targeted phototherapy (VTP) of a target site in a subject, comprising administering a VTP -effective drug to a feeder artery of the target site at an amount sufficient for vascular targeted phototherapy.
Nucleic acid molecules comprising a heterologous promoter and an open reading frame encoding a T cell receptor (TCR) alpha chain comprising a CDR-A3 of SEQ ID NO: 3, 5 or 9 and an open reading frame encoding a TCR beta chain comprising a CDR-B3 of SEQ ID NO: 4, 6 or 10. Isolated populations of T cells and compositions comprising the nucleic acid molecules as well as methods of treating cancer are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/00 - Drugs for immunological or allergic disorders
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
28.
MICROPUMP WITH ELECTROSTRICTIVE MATERIAL ACTUATION
>n nnn n to generate a wave travelling of amplitude S along the capillary tube section. The micro-pump can be configured to operate as a travelling wave micro-pump (TWµP) by adjusting the driving signal so that 2S < 0,2h or to operate as a peristaltic micro-pump (PµP) by adjusting the driving signal so that 2S = 0,5h.
A device comprising a continuous planar surface, wherein at least five different amounts of biomolecule-immobilizing moieties are patterned on a surface area of between 0.05 mm² - 50 mm² at distinct locations of said continuous planar surface, wherein a difference between a highest amount and a lowest amount of said five different amounts is at least 5 fold. Use for measuring binding affinity between two biomolecules is disclosed.
An albumin protein is provided. The albumin protein is soluble when expressed in bacteria and characterized by increased thermostability as compared to wild type human serum albumin (HSA). Also provided are nucleic acid molecules encoding the albumin protein, compositions comprising the albumin protein and uses thereof.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A method of crystallization to produce crystalline spherulites of a small heterocyclic compound with molecular weight in the range of 100 to 300 g/mol, wherein said compound is either monocyclic or has a fused bicyclic ring structure, with at least two nitrogen heteroatoms, comprising the steps of: changing the pH of a strongly alkaline or strongly acidic water-in-oil emulsion that contains said compound in its solubilized form, phase inverting the emulsion by increasing the water-to- oil ratio, wherein the pH is changed and brought to a range across which the neutral form of said compound is stable and insoluble, and collecting the crystalline spherulites. Crystalline spherulites composed of small heterocyclic compound such as guanine or xanthine are also provided.
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
C30B 29/66 - Crystals of complex geometrical shape, e.g. tubes, cylinders
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
The present invention is directed towards degumming a silk fiber, obtaining high quality silk fibroin solutions and the reconstitution of silk. The invention further relates to a method of accurately and precisely determining mechanical properties of biological fibers such as silk fibers.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
D01F 4/02 - Monocomponent artificial filaments or the like of proteinsManufacture thereof from fibroin
33.
METHODS AND SYSTEM FOR STIMULATING ROOT EXUDATION IN PLANTS
Provided is a plant exudate, methods for obtaining a plant exudate by inducing the plant to secrete an exudate and systems for the collection of a plant exudate which include: one or more plant container including at least two discrete compartments each configured to accommodate a split root of a plant, the compartments being a root stimulating compartment including one or more input being in fluid communication with at least a source of a plant root stimulant, and a root exudate harvesting compartment, and a root exudate collection compartment in fluid communication with the root exudate harvesting compartment.
A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07J 17/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta[a]hydrophenanthrene skeleton
34.
OPTICAL BEAM POSITIONING AND CONTROL FOR QUANTUM COMPUTING
Apparatus (20) for quantum computing includes an ion trap (24), which is configured to hold a first array of ions (40) in respective positions along an array axis (38). A radiation source (28) is configured to emit a second array of beams of coherent radiation, including first beams having respective first intensities (64) and having frequencies chosen to excite selected internal transitions of the ions and second beams having second intensities (66) at least ten times greater than any of the first intensities, and to switch respective locations of the first and second beams within the second array. Optics (82) focus the beams into the ion trap such that each beam in the second array is incident on a respective ion in the first array.
C01B 33/193 - Preparation of finely divided silica neither in sol nor in gel formAfter-treatment thereof by acidic treatment of silicates of aqueous solutions of silicates
Described herein are anti-human ATP6VIB2 antibodies. The antibodies can be used to target senescent cells. Thus, the anti-ATP6VIB2 antibodies would be useful in treating diseases and conditions associated with cellular senescence.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
37.
DIAGNOSTIC METHODS BASED ON ANTIBODY REACTIVITY TO ENAMEL MATRIX PROTEINS AND KAPPA-CASEIN
Provided herein are diagnostic methods testing the presence of autoantibodies against various enamel matrix proteins and also against bovine and human kappa-casein in body samples, particularly body fluid samples. In particular, diagnosis and management of autoimmune-mediated enamel dysplasia are provided, and also diagnosis and management of celiac disease.
Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
ULTRAFAST MOLECULAR INVERSION PROBE-BASED TARGETED SEQUENCING ASSAY FOR LOW VARIANT ALLELE FREQUENCY
Provided herein is an improved molecular inversion probe protocol, exhibiting reduced noise, high specificity and sensitivity and improved coverage at GC-rich regions.
THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL R (Israel)
HARVESTR TECHNOLOGIES LTD. (Israel)
Inventor
Fluhr, Robert
Alkan, Noam
Povarenov, Lena
Duanis Assaf, Danielle
Chowdhary, Pankaj
Admati, Gal
Bar Lavan, Yael
Abstract
The present invention is directed to an anti-fungal composition including a plurality of particles including: at least one dsRNA molecule including a nucleic acid sequence complementary to at least one transcript of at least one essential gene of a fungus, and methods of using same.
A system and method for detecting at least one cardiac anomaly includes a specifically configured computer hardware arrangement configured to receive ultrasound imaging information related to a heart of a patient and to use at least one neural network trained on multiple recognition and analysis procedures to detect at least one anomaly and/or to classify a severity of at least one anomaly.
Provided herein is a method for obtaining a humanized antibody based on a non-human antibody having an affinity to an antigen of interest, that starts from an experimental or model structure, grafts the non-human CDRs on a library of human frameworks and uses restrained/constrained atomistic simulations to relax and rank the designs by energy.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A sleep bruxism reduction system constituted of: a bruxism detection apparatus configured to detect sleep bruxism in a user; an odor dispensing device; and a control unit, wherein the control is unit is configured, responsive to the detection of a sleep bruxism event in the user by the bruxism detection apparatus, to control the odor dispensing device to dispense a predetermined amount of odorous material, thereby reducing sleep bruxism in the user.
Methods of controlling biological processes by altering the electric field gradient in a test chamber are disclosed. A portion of a surface of the test chamber is attached to at least one immobilized component of the biological process. Microfluidic devices capable of same are also disclosed.
Some embodiments relate to a computer system for determining a structural image of a sample. The computer system is configured to receive and process raw measured data produced by a scanning microscope and being indicative of at least one scan dataset (IM)N acquired in a scan session and corresponding to a sequence of N measurements on a sample located in proximity to a focal plane of the scanning microscope. Each measurement includes data provided by M detection channels associated with M-segment detector (M≥3). The computer system includes a data analyzer capable of processing at least one scan dataset to compensate image shifts induced by off-axis detection channels for sample features at defocus plane to thereby obtain data indicative of parallax corrected scan image of the sample which enables separation between phase and depth information and extraction of a depth contrast image of the sample from the single scan dataset.
G01N 23/041 - Phase-contrast imaging, e.g. using grating interferometers
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
Provided herein are methods of culturing ex-vivo tissue, comprising culturing a tissue slice under a highly oxygenated atmosphere in the presence of an amount of an agent and agitating the culture. Also provided are methods of determining a therapeutically effective dose of an agent in the treatment of a disease or disorder using the ex-vivo tissue culture method.
Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.
The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
Methods of inhibiting eIF4G1 binding to eIF1, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4G1-eIF1 binding and there use in treating disease are also provided.
Disclosed herein are broad-spectrum Coronavirus entry inhibitor compounds and methods of use thereof. Methods disclosed herein include inhibiting Coronavirus infection, treating a Coronavirus infection, and treating a subject at risk of contracting a Coronavirus infection. The compounds described herein target entry of Coronaviruses downstream of binding of the viral receptor.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (Israel)
Inventor
Aharoni, Asaph
Sonawane, Prashant
Cardenas, Pablo D.
Burdman, Saul
Abstract
Disclosed herein are genetically modified plants having altered biological activity of 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-β-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Methods of producing these genetically modified plants are also disclosed.
There is provided an isolated fungus belonging to the genus Kazachstania, a composition comprising same, and methods of using same, such as for preventing or treating an infection, a disease, or both.
An assembly, system, and method for photodynamic therapy (PDT) of a target tissue utilizing a delivery apparatus and a displacement control arrangement. The delivery apparatus comprises a flexible needle device with an elongated flexible tube having a fiber-receiving lumen, extendable in a proximal-distal direction along a delivery axis, and with a pointed, needle-like distal tip for penetrating said tissue. An optical fiber is insertable and axially displaceable within said lumen and couplable at its proximal end to a light source, emitting a PDT-effective light at a wavelength applicable for said PDT. The fiber's distal end portion has a light-diffusing section for emitting light from within the fiber in one or more directions and has one or more X-ray markers. The displacement-control arrangement is couplable to a proximal portion of the flexible needle device and to a proximal portion of the optical fiber accommodated within the flexible needle device with the proximal portion projecting out of the proximal end of the flexible needle device, and comprises an axial displacement arrangement configured for controlled axial displacement of said delivery apparatus. The delivery apparatus may also comprise a delivery catheter extending in a proximal-to-distal direction and has a working channel that can accommodate the flexible needle device.
A co-polymeric compound represented by Formula (I): wherein the variables are described in the specification and claims, a composition comprising a hydrogel or a composite material containing a hydrogel what has incorporated therein the co- polymeric compound and a process of preparing such a composition, a method of lowering a friction coefficient of a hydrogel or of a composite material containing a hydrogel effected by forming the hydrogel in the presence of the co-polymeric compound, a method of inhibiting biofilm formation on a surface of a substrate comprising contacting the substrate with the composition or composite material, and an article-of-manufacturing comprising the composition or composite material, are provided.
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
A system and methods for electron beam imaging or electron beam spectroscopy. The system comprising: a transmission electron microscope (TEM) having a back focal plane; one or more laser-based devices, configured to shift a predetermined portion of an electron wave to an energy that is different from the energy originally provided by the electron source of the TEM; and an electron energy filter that is configured to accept electron waves, at the energy provided by the electron source of the TEM, and further configured to reject electron waves shifted to a different energy by the laser device.
Provided herein a biodegradable composite comprising a biodegradable polymer and bio-crystals, wherein the bio-crystals are in a concentration of between 1 wt % to 50 wt % of the biodegradable polymer.
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (Israel)
Inventor
Erez, Ayelet
Goldman, Omer
Hajaj, Emma
Schroeder, Avi
Abstract
Methods of predicting clinical outcome in a subject suffering from cancer, detecting non-liver cancer in a subject, and methods of treating or preventing cancer or cancer-associated cachexia are provided. Synthetic lipid nanoparticles encapsulating an mRNA encoding for HNF4A and composition comprising same are also provided.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
58.
GENETICALLY MODIFIED BACTERIA FOR MULTI-MODAL SECRETION OF A NEOANTIGEN
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
C12N 15/78 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
Provided herein a supramolecular assembly comprising a solid porous particle comprising a single-stranded polynucleotide encapsulated by non-covalent organic structure. Specifically, the non-covalent organic structure is melamine-cyanurate, and the single-stranded polynucleotide is ssDNA or ssRNA.
Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more of the molecule 1′-2′ glycosyl cyclic adenosine diphosphate ribose (1′-2′ gcADPR), 1′-3′ gcADPR or Tad1 protein.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
61.
COMPOSITE COMPRISING AN ELASTIC POLYMERIC SUBSTRATE AND METAL NANOSTRUCTURES AND METHOD OF MAKING SAME
A composite, an article comprising the composite, and a method of making the composite are disclosed. The composite may include an elastic polymeric substrate and metal nanostructures attached to a surface of the elastic polymeric substrate; wherein: each of said metal nanostructures comprises a first portion embedded within the elastic polymeric substrate and a second portion exposed to an ambient; said metal nanostructures have lateral dimension between 1 to 1000 nm, said metal nanostructures have a thickness of between 5 to 200 nm.
A polymeric compound is disclosed herein, having the general formula I:
A polymeric compound is disclosed herein, having the general formula I:
A polymeric compound is disclosed herein, having the general formula I:
wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.
C08F 130/02 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Nucleic acid molecules comprising a heterologous promoter and an open reading frame encoding a T cell receptor (TCR) alpha chain comprising a CDR-A3 of SEQ ID NO: 3 and an open reading frame encoding a TCR beta chain comprising a CDR-B3 of SEQ ID NO: 4 are provided. Isolated populations of T cells and compositions comprising the nucleic acid molecules as well as methods of treating cancer are also provided.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
One or more pMPC conjugate(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided. Use of the pharmaceutical composition for delivering a cargo (e.g. a nucleotide) to a subject is also provided.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Genetically modified phages are provided. Accordingly, there is provided a genetically modified phage comprising a polynucleotide encoding an anti-defense system polypeptide. Also provided are methods of producing and using same.
This invention is directed to a method of electrocatalytic reduction of dinitrogen (N2) to ammonia using a poly oxometalate catalyst, an alkali metal cation and a donor of a proton and/or an electron.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
The present invention relates to a quantum computing device based on manipulating Majorana Zero Mode excitations (MZMs) in topological superconducting regions formed in a tapered nanowire or similar structure. The tapering of the NW structure results in the formation of discrete regions of topological superconductivity having MZMs at their end boundaries, and thereby facilitates establishing the MZMs without delicate tuning procedures. A quantum swap gate is provided, utilizing two such structures in contact and disposed orthogonally to one another. Applying a magnetic field selectively lengthens the region of one structure while shortening the region of the other, allowing voltage and magnetic field changes to manipulate and interchange the MZM quantum states of the two structures to effect the swap operation.
Using a pre-trained and fixed Vision Transformer (ViT) model as an external semantic prior, a generator is trained given only a single structure/appearance image pair as input. Given two input images, a source structure image and a target appearance image, a new image is generated by the generator in which the structure of the source image is preserved, while the visual appearance of the target image is transferred in a semantically aware manner, so that objects in the structure image are “painted” with the visual appearance of semantically related objects in the appearance image. A self-supervised, pre-trained ViT model, such as a DINO-VIT model, is leveraged as an external semantic prior, allowing for training of the generator only on a single input image pair, without any additional information (e.g., segmentation/correspondences), and without adversarial training. The method may generate high quality results in high resolution (e.g., HD).
A nanowire having a magnetic property is disclosed. The nanowire comprising: a ternary Zintl phase of a stoichiometric formula of X3Y2Z4, wherein the ternary Zintl phase is in a crystalline state; and wherein: X is selected from Eu, Ca, Sr, and Ba; ¥ is In or Al; and Z is As or P.
C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
Provided herein a PINCH (Polymerization Inducing Chimera) compound targeting a homomeric protein of interest, wherein the PINCH compound comprises at least two protein binder groups that target the homomeric protein of interest and induces its polymerization.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
A system (20) for quantum computing includes an array of qubits (40) and a radiation source (28), which applies simultaneously to multiple qubits in the array radiation including a set of spectral components in multiple vibrational sidebands of an internal transition frequency of the qubits with different, respective complex amplitudes. The sidebands are generated by a group of the normal modes having a minimal spacing Δf between the respective vibrational frequencies. A controller (32) initializes a multi-qubit gate, including at least five of the qubits, to an initial state and drives the radiation source to apply the radiation to each of the qubits with respective complex amplitudes of the spectral components in the set selected so as to switch the multi-qubit gate to a target state within a gate time that is less than 50/Δf.
Non-invasive methods of detecting pathology of the bone marrow comprising receiving a metacell model of a plurality of metacell types based on single cell RNA sequencing (scRNA-seq) of CD34 positive cells from peripheral blood and comparing it to control values of metacells of CD34 positive cells from peripheral blood of healthy subjects are provided. Non-invasive methods of predicting the percentage of blasts in the bone marrow and of calculating an IPSS-M risk score are also provided, as are systems for performing the methods of the invention.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]
This invention provides nanostructures comprising a base. and nano-protrusions attached to the base. The invention further provides arrays of such nanostructures on substrates. Also provided by this invention are analysis and catalysis. separation and purification systems and methods. comprising or making use of the novel nanostructures. Particles and films comprising nano-protrusions are included in this invention as well.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
YEDA RESEARCH AND DEVELOPMENT CO. LTD. (Israel)
Inventor
Vandenbark, Arthur, A.
Kulkarni, Rajan
Meza-Romero, Roberto
Pellegrino, Bianca
Shachar, Idit
Abstract
Methods of treating a subject with cancer with a recombinant polypeptide including an antigenic peptide covalently linked to a DRα1 domain or portion thereof comprising a glutamine residue at a position corresponding to amino acid 45 of SEQ ID NO: 1 or SEQ ID NO: 2 are provided. In some examples, the subject is resistant to immune checkpoint blockade treatment and/or has a tumor that does not express a BRAF mutation.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
77.
PROPEPTIDE OF LYSYL OXIDASE FOR TREATMENT OF CANCER
A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to medical assemblies and devices designed to capture and remove particulates and debris from a patient's body. In one example, a medical assembly can include a delivery shaft defining a working channel, and a debris removal device axially movable through the working channel. The debris removal device includes a main shaft and at least one debris capture segment attached to the main shaft. The debris capture segment includes a plurality of outwardly biased filaments, and is configured to transition between a compacted state when disposed inside the working channel or inside a lumen of a sleeve that can be optionally disposed around the main shaft, and an expanded state when exposed out of the working channel and/or lumen of the sleeve.
The present invention provides polynucleotide sequences encoding a protein belonging to a decarboxylating (DC) enzyme family and/or a protein belonging to a hydroxylating (CYP) enzyme family. Further provided are a plasmid including the polynucleotide, a transgenic cell, and/or a plant including same. Further provided is a method for synthesizing mescaline.
This invention is directed to a catalytic hydrogenation process for the preparation of 1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)-2-(tert-butylamino)ethanol, which is an intermediate for the preparation of Salbutamol.
This invention is directed to a catalytic hydrogenation process for the preparation of 1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)-2-(tert-butylamino)ethanol, which is an intermediate for the preparation of Salbutamol.
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
81.
ACTIVE MACROLIDE ANTIBIOTIC COMPOUNDS AGAINST PATHOGENS
C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Liposomes, and pharmaceutical compositions comprising same, for use in treating biofilm in a subject in need thereof are disclosed herein. The liposomes comprise a bilayer-forming lipid; a polymer-lipid conjugate having the general formula I, as described and defined in the specification; a positively-charged lipidic agent, incorporated within a lipid bilayer and/or on a surface of the liposome; and a therapeutically active agent, bound to a surface of the liposome and/or within a lipid bilayer and/or core of the liposome.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
Methods for decompressing a multiplexed-image, of C different channels, acquired to identify P targets in a tissue sample, where the targets are combinatorically labeled by at least C different labeling-elements, which are configured to be detected by the C different channels, and where P > C. The method comprising processor implemented step of: applying the multiplexed-image as an input to a trained NN. The NN is configured to output a tensor B, having P binary -images each having binary-pixels, each binary -image p per a different molecule p of the P molecules (where p = l,2,...,Py, wherein a pixel (ij; i = 1,2, = 7,2, in a binary-image p having a value of one (7) indicates that pixel (zj) is expected to contain a signal of its associated molecule p.
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
84.
MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES
A multispecific antibody is provided. The antibody comprises a first antigen binding moiety, which specifically binds to an immune checkpoint protein on intratumor T cells and a second antigen binding moiety which specifically binds to a conventional dendritic cell 1 (cDC1). Also provided are uses of such antibodies in cancer treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to catheter assemblies (100) designed to provide fluid communication between an organ in a patient's body and the external environment. Such a catheter assembly (100) includes an indwelling catheter (102) equipped with an anchoring mechanism (110) at a distal portion (104) thereof and an external tube (150) configured to frictionally engage with a proximal end portion (128) of the indwelling catheter. The frictional force between corresponding engagement surfaces of the indwelling catheter (102) and the external tube (150) is configured to allow disengagement therebetween in response to a pull force equal to or greater than a threshold separating pull force not greater than 20N for a duration of no more than 10 seconds, wherein the threshold separating pull force is designed to be lower than the pull force required to cause dislodgment of the indwelling (102) catheter from the patient's body.
The disclosure presented herein provides DNA constructs, recombinant cells comprising thereof, system comprising thereof, bacterial probes, and/or a recombinant cell decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying cells, preferably bacteria cells, and methods for using thereof.
Provided herein noncovalent hybrids comprising carbon nanotubes (CNTs) and aromatic compounds, composites based on them, process of preparation and uses thereof; wherein the hybrids possess superior mechanical and electrical properties.
The present invention is directed to a pharmaceutical composition including a therapeutically effective amount of an agent capable of inhibiting an active site of a matrix metalloprotease (MMP-7) protein, and use of same in a method for treating endometriosis or ameliorating at least one symptom associated therewith, in a subject in need thereof.
A method of analyzing nucleosomes is provided. The method comprising: (a) isolating a plurality of nucleosome molecules from a biological sample; (b) enzymatically linking adenine nucleotides to free DNA ends of the plurality of nucleosome molecules, wherein at least a portion of the adenine nucleotides comprises a label, such that the plurality of nucleosome molecules become attached to a labeled poly(A) tail; (c) hybridizing the plurality of nucleosome molecules attached to the labeled poly(A) tail to a solid support coated with poly(T); and (d) imaging the solid support, whereby the plurality of nucleosome molecules are visualized.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6804 - Nucleic acid analysis using immunogens
Systems and methods for a quantum computing include a plurality of photonic processing stages, a plurality of heralding-free connections, and circuitry configured to regulate photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage. Each heralding-free connection is located between adjacent photonic processing stages. Each photonic processing stage includes at least two of an optical switch, a beam splitter, a waveguide or a photon generator. Methods include transmitting or receiving a plurality of photons via a plurality of heralding-free connections, and regulating photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage.
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
92.
METHOD AND SYSTEM FOR DETERMINING EFFICACY OF TREATMENT BY A PREDETERMINED SUBSTANCE
A system and method of determining efficacy of treatment by at least one processor may include receiving, from at least one camera, images depicting motion of an animal that may be treated with a predetermined substance of interest. Said processor may extract from the images, a plurality of motion features representing motion of at least one specific body part of the animal, and apply a dimensionality reduction algorithm on the plurality of motion features, to obtain a latent vector representing the plurality of motion features in a latent space. The latent vector may include a plurality of latent features. Said processor may subsequently calculate a value of a behavioral indicator, representing a behavior of the animal, based on the latent features of the latent vector, and determine efficacy of the treatment based on the behavioral indicator value.
A quantum computing system, method, and computer readable medium involves initializing a state of a resonator-coupled quantum emitter having at least four levels arranged in an N-configuration, the N-configuration having a first ground state, a second ground state, a first excited state and a second excited state. A frequency of a first transition between the first ground state and the first excited state is tuned, a frequency of a second transition between the second ground state and the second excited state is tuned, and a frequency of a third transition between the second ground state and the first excited state is tuned. A plurality of photons are fed at a frequency corresponding to the frequency of the second transition, thereby entangling the plurality of photons to the resonator-coupled quantum emitter. Likewise, a photon at a frequency corresponding to the frequency of at least one of the first transition or the third transition is fed, thereby mapping a state of the resonator-coupled quantum emitter into a photon.
HEALTH CORPORATION NEXT TO SHAMIR MEDICAL CENTER (ASSAF HAROFEH) (R.A.) (Israel)
Inventor
Berkowitz, Brian
Heller, Lior
Abstract
The present disclosure relates to drainage devices designed to enable drainage of bodily fluids while reducing the risk of drainage openings being clogged by tissues surrounding the device. In one example, a drainage device comprises a drainage tube and a porous plug attached to a distal portion of the drainage tube. The porous plug defines a plurality of pores that includes interconnected channels fluidly connecting between pore outer openings along an exposed outer surface of the plug, and pore inner openings along an inner uncovered surface of the plug, such that upon application of suction to the drainage tube, bodily fluid can flow, through the pore outer openings, pore interconnected channels, and pore inner openings, towards a lumen of the drainage tube.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61M 27/00 - Drainage appliances for wounds, or the like
Systems and methods for generating photonic graph states for quantum computing include coupling a quantum emitter to a cavity, generating a first dirty photon having a first temporal profile, using the first dirty photon to form a first photonic qubit, generating a second dirty photon having a second temporal profile, using the second dirty photon to form a second photonic qubit, using the quantum emitter coupled to the cavity to entangle the first photonic qubit with the second photonic qubit to form a pair of entangled photonic qubits, and using the pair of entangled photonic qubits for quantum computation.
A quantum computing system, method and computer readable medium involve a vacuum chamber, an atom source input associated with the vacuum chamber, a Photonic Integrated Circuit (PIC) having an interaction region configured to interact with an atom from the atom source, a coupling location for atom positioning, a trapping laser for trapping the atom in the coupling location, an excitation laser for manipulating an electronic state or a nuclear state of the atom, a waveguide for guiding input light to the coupling location, and an output channel for directing quantum light generated at the coupling location, out of the vacuum chamber as a resource for quantum computing. The coupling location is associated with the PIC, and the interaction region of the PIC is arranged for at least partial exposure to the vacuum.
A system for predicting probability for developing a liver associated disease, comprises a data processor which obtains parameters extracted from a body liquid test applied to a healthy subject, and feeds a machine learning procedure with the parameters. The machine learning procedure is trained for predicting probabilities for liver associated disease, and the processor receives from procedure an output indicative of a probability that the subject is expected to develop a liver associated disease.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
98.
A COMPOSITE COMPRISING CARBON NANOTUBES AND USES THEREOF AS A CATHODE
Provided herein a composite comprising a multi-layered structure comprising at least one layer of multi-walled carbon nanotube (MWCNT) and at least one layer of single-walled carbon nanotube (SWCNT); and its use as a cathode for e.g. LSBs (lithium sulfur batteries).
Board of Regents, The University of Texas System (USA)
Inventor
Reisner, Yair
Rosen, Chava
Shezen, Elias
Orgad, Ran
Milman Krentsis, Irit
Su, Xiaohua
Yadav, Raj Kumar
Zheng, Yangxi
Abstract
Multipotent lung progenitor cells for lung regeneration are provided. Accordingly, there are provided methods of expanding in culture an isolated population of pulmonary cells, methods of qualifying suitability of an isolated population of pulmonary cells for administration to a subject in need thereof, and methods of generating an isolated population of pulmonary cells comprising selecting a cell population being double positive for expression of epithelial and endothelial cell markers. Also provided are isolated populations of pulmonary cells, pharmaceutical compositions comprising same and uses of same.
A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.
